Sustained functional recovery one year after TFCC debridement with adjuvant umbilical cord-mesenchymal stem cells and secretome therapy: a case report.

INTRODUCTION AND

IMPORTANCE

Triangular fibrocartilage complex (TFCC) tears can significantly impair wrist stability and daily function. Regenerative medicine, particularly mesenchymal stem cell-based therapy, may complement traditional surgical approaches such as debridement with synovectomy to enhance recovery.

PRESENTATION OF CASE: This report presents the 1-year follow-up of a 41-year-old male with a TFCC tear previously treated with debridement synovectomy followed by intra-articular umbilical cord-derived mesenchymal stem cells (UC-MSCs) and UC-MSC-derived secretome. UC-MSCs were selected for their regenerative potential and well-established roles in tissue repair. Clinical evaluations were performed pretreatment, at 6 months, and at 12 months. Outcomes were assessed using magnetic resonance imaging (MRI), the Visual Analogue Scale (VAS), and the Disabilities of the Arm, Shoulder and Hand (DASH) score. At 12 months, the patient maintained a VAS score of 0, indicating complete and sustained pain resolution. Functional improvement continued, with the DASH score progressing from 12 at 6 months to 5.8 at 12 months. MRI findings demonstrated stable postoperative healing without recurrent injury or degenerative change.

CLINICAL DISCUSSION: One-year follow-up shows near-complete restoration of daily wrist function. No adverse events related to UC-MSC or secretome administration occurred. These results suggest that UC-MSC-based therapy may provide durable regenerative benefits when used as an adjuvant to debridement with synovectomy.

CONCLUSION

One year after surgery supplemented with UC-MSC and secretome therapy, the patient demonstrates sustained pain relief and progressive functional recovery. This case supports the potential role of UC-MSC-based therapy in enhancing long-term outcomes in TFCC injury, warranting further investigation.